SCHEMBL5632090

SCHEMBL5632090

CC(C)(C)OC(=O)NCC(O)CNS(=O)(=O)c1ccccn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.43
KAT6A Q92794 1/20 0.42
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.41
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
SYK P43405 1/20 0.39
CA7 P43166 1/20 0.39
CA14 Q9ULX7 1/20 0.39
CTSK P43235 6/20 0.39
ALOX5AP P20292 1/20 0.39
FEN1 P39748 1/20 0.39
PCSK9 Q8NBP7 1/20 0.39
MALT1 Q9UDY8 1/20 0.38
ACACB O00763 1/20 0.38
CTSB P07858 2/20 0.38
CTSS P25774 2/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6618230 0.87 CTSK (0.47) CTSKCTSBCTSS
SCHEMBL6635507 0.84 CTSK (0.46) CTSKCTSBCTSS
SCHEMBL15124929 0.83 ALOX5AP (0.49) L3MBTL1KAT6ACA12CA1CA7
SCHEMBL7467714 0.83 CTSK (0.46) CTSKCTSBCTSS
SCHEMBL14384114 0.82 L3MBTL1 (0.44) L3MBTL1KAT6ATSHRHTTCA12
SCHEMBL14384115 0.82 L3MBTL1 (0.44) L3MBTL1KAT6ATSHRHTTCA12
SCHEMBL5632717 0.82 L3MBTL1 (0.50) L3MBTL1KAT6AHTTCTSKMEN1
SCHEMBL5630355 0.82 L3MBTL1 (0.50) L3MBTL1KAT6AHTTCTSKMEN1
SCHEMBL14384120 0.77 CTSK (0.44) L3MBTL1KAT6ACTSKCTSBCTSS
SCHEMBL14384118 0.77 CTSK (0.44) L3MBTL1KAT6ACTSKCTSBCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7288541-B2 Propylcarbamate derivatives as inhibitors of serine and cysteine proteases SMITHKLINE BEECHAM CORPORATION (US) 2007-10-30 US disclosed
US-7288541-B2 Propylcarbamate derivatives as inhibitors of serine and cysteine proteases SMITHKLINE BEECHAM CORPORATION (US) 2007-10-30 US disclosed
US-7288541-B2 Propylcarbamate derivatives as inhibitors of serine and cysteine proteases SMITHKLINE BEECHAM CORPORATION (US) 2007-10-30 US disclosed
US-20050043368-A1 Propylcarbamate derivatives as inhibitors of serine and cysteine proteases SMITHKLINE BEECHAM CORPORATION 2005-02-24 US disclosed
EP-1448554-A1 PROPYLCARBAMATE DERIVATIVES AS INHIBITORS OF SERINE AND CYSTEINE PROTEASES SmithKline Beecham Corporation (US) 2004-08-25 EP disclosed
WO-2003031437-A1 PROPYLCARBAMATE DERIVATIVES AS INHIBITORS OF SERINE AND CYSTEINE PROTEASES SMITHKLINE BEECHAM CORPORATION (US) 2003-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043368-A1 Propylcarbamate derivatives as inhibitors of serine and cysteine proteases CTSK, CTSB, CTSS L3MBTL1 1234/4885KAT6A 2379/4885TSHR 4310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.